Introduction
Opioid substitution therapy (OST) is substantially more effective than abstinence-based treatment for patients with opioid use disorders. Buprenorphine and methadone both appear to be equally effective as OST, with buprenorphine being associated with less sedation and respiratory depression. However, as psychoactive substances, both methadone and buprenorphine have the potential to affect cognitive and psychomotor function.

Cognitive function
Opioid medications may affect cognitive function because their mechanism of action is mediated via the activation of opioid receptors, which integrates pain modulation with other CNS processes, including cognition. Despite methodological problems with the literature, a meta-analysis of observational studies suggests that chronic opioid use is associated with deficits in certain neuropsychological domains. For example, some cognitive impairment is common among chronic pain populations receiving long-term opioid treatment, and among chronic users of illicit opioids. In terms of OST, evidence from two small prospective studies indicates less impairment of cognitive function in patients receiving buprenorphine or methadone than in individuals dependent on illicit opioids. A preliminary study evidence also suggests that opioid-dependent patients experience improvements in neuropsychological function after starting OST with either methadone or buprenorphine. However, most drug-induced cognitive impairments in patients with substance dependency diminish or disappear with drastic reduction in consumption or abstinence.

According to a recently published comprehensive systematic review of clinical studies that assessed the cognitive effects of labelled medications used to treat drug dependency, there is a lack of large comparative trials that have assessed the cognitive effects of OST medications. Additionally, independent of sedative effects, it may be difficult to separate the possible cognitive effects of the OST medication from the effects of drug abstinence itself. Nonetheless, some preliminary conclusions have been drawn from the available clinical study evidence. Both buprenorphine and methadone appear to impair executive function and general cognition in opioid-dependent patients compared with healthy control subjects. However, in direct comparisons of buprenorphine- and methadone-treated patients, while some studies have demonstrated no differences between the two medications, most have demonstrated less impairment of cognitive function with buprenorphine.

An improvement of certain cognitive abilities with buprenorphine—compared with methadone-based OST was even evident in a few studies. In a 12-month prospective study, buprenorphine-treated patients improved their performance in working memory to reach a level similar to that of healthy controls while methadone-treated patients remained impaired. Another study reported that OST patients who received buprenorphine performed better than methadone-treated patients in terms of decision-making capacity tested in a gambling task (although not differently compared with healthy control subjects).

More recently, a small study assessed whether neuropsychological changes over time in opioid-dependent individuals are linked with depressive symptomatology or adherence to OST with buprenorphine. Increased adherence to buprenorphine, but not depressive symptomatology, was associated with improved neuropsychological functioning. Therefore, facilitating adherence to buprenorphine may benefit learning and memory functioning in OST patients. Furthermore, a conclusion of a recent review of studies that assessed the effectiveness and side effect profiles of methadone and buprenorphine OST in the primary care setting was that buprenorphine can be recommended for opioid-dependent patients receiving buprenorphine or methadone than in individuals dependent on illicit opioids.

Psychomotor function and driving-related skills
Although there is a theoretical potential for opioid agonists to affect driving, a recent comprehensive systematic review of the literature suggests that, notwithstanding the need for more prospective studies, driving-related psychomotor skills are not impaired in people receiving regular therapeutic opioids. This finding is consistent with an earlier literature review that concluded that opioids do not appear to impair driving-related skills in opioid-dependent patients. The influence of long-term buprenorphine use on psychomotor and cognitive function related to driving ability has been assessed in two prospective comparative studies. Compared with matched controls (untreated healthy volunteers), neither opioid-dependent patients receiving buprenorphine OST nor non-cancer patients receiving buprenorphine for chronic pain showed significant impairment of complex psychomotor or cognitive performance tests. These findings are supported in a recent prospective study in which the on-the-road driving performance of chronic


dr Peter Griffiths

Peter graduated from the Otago Medical School in 1984. After several years working in general practice, he was involved in doing some part-time service for the Christchurch alcohol and drug service. Gradually this commitment grew as he found it was a rewarding, enjoyable and challenging arena of work. He is now engaged in a peripatetic practice, serving three OST programmes across the mainland.

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our CPD page.

ABOUT RESEARCH REVIEW
Research Review is an independent medical publishing organisation producing electronic publications in a wide variety of specialist areas. Research Review publications are intended for New Zealand medical professionals.

SUBSCRIBE AT NO COST TO ANY RESEARCH REVIEW
NZ health professionals can subscribe to or download previous editions of Research Review publications at www.researchreview.co.nz

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

www.researchreview.co.nz
Buprenorphine and methadone are equally effective as OST in opioid-dependent patients, with buprenorphine having a lower risk of overdose. Limited clinical study evidence suggests less cognitive function impairment with buprenorphine than with methadone in OST patients. Limited clinical study evidence suggests minimal impairment of driving skills with long-term use of buprenorphine. The fitness of patients receiving OST to drive should be based on an individual assessment. Buprenorphine may be a better OST option for patients with occupations requiring a high degree of cognitive function or psychomotor performance.

TAKE-HOME MESSAGES

- Buprenorphine and methadone are equally effective as OST in opioid-dependent patients, with buprenorphine having a lower risk of overdose.
- Limited clinical study evidence suggests less cognitive function impairment with buprenorphine than with methadone in OST patients.
- Limited clinical study evidence suggests minimal impairment of driving skills with long-term use of buprenorphine.
- Buprenorphine may be a better OST option for patients with occupations requiring a high degree of cognitive function or psychomotor performance.
- The fitness of patients receiving OST to drive should be based on an individual assessment.

REFERENCES